Plgf and sflt-1 as prognostic parameters for cardiovascular diseases
CA 2585271 C · Owner: Zeiher, Andreas M. · Inventors: Zeiher, Andreas M.; Heeschen, Christopher; Dimmeler, Stefanie
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention refers to a use of an ex vivo method comprising the determination of P1GF , and sFlt-1 in a sample for diagnosis risk stratification and/or monitoring of a vascular disease , with atherosclerotic etiology in particular a coronary heart disease such a unstable angina , pectoris or myocardial infarction and/or for estimation of the probability of developing such a , disease, as well as for identification of a patient supposed to benefit from a therapy by agents , reducing the risk for a cardiovascular disease. In the method (i) a ratio of P1GF = high : sFlt-1 , = low, and/or (ii) a P1GF concentration in the upper two tertiles of a reference collective, and an , …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 25, 2005 and granted August 28, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 25, 2025.
- Certificates of supplementary protection extend only drug patents, and it isn't classified as one.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.